Cardiol Therapeutics (TSE:CRDL) Issues Earnings Results

Cardiol Therapeutics (TSE:CRDL) released its quarterly earnings results on Tuesday. The company reported C($0.07) earnings per share for the quarter, FiscalAI reports.

Cardiol Therapeutics Price Performance

Shares of TSE:CRDL traded up C$0.04 during trading on Thursday, reaching C$1.99. The company had a trading volume of 134,797 shares, compared to its average volume of 106,754. Cardiol Therapeutics has a 12 month low of C$1.09 and a 12 month high of C$2.17. The company has a current ratio of 3.89, a quick ratio of 6.84 and a debt-to-equity ratio of 1.40. The stock has a market capitalization of C$222.24 million, a P/E ratio of -4.85 and a beta of 0.94. The company has a fifty day moving average of C$1.42 and a two-hundred day moving average of C$1.45.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company’s lead drug candidate, CardiolRxTM (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure.